Form 4: Eli Lilly Director J Erik Fyrwald Acquires Shares Under Directors' Deferral Plan

Director J Erik Fyrwald acquired 11.569 shares of Eli Lilly & Co common stock at $857.2 per share on February 18, 2025, under the Lilly Directors' Deferral Plan.

Summary

• On February 18, 2025, J Erik Fyrwald, a director of Eli Lilly & Co, acquired 11.569 shares of common stock.
• The acquisition was made at a price of $857.2 per share.
• These shares were acquired under the Lilly Directors' Deferral Plan in lieu of cash compensation.
• Following the transaction, Fyrwald directly owns 72,683.121 shares of Eli Lilly & Co.
• The acquired shares will be settled in shares of common stock following Fyrwald's separation from service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's participation in the deferral plan suggests confidence in the company, but it's a routine transaction.

Positives

• The director's participation in the Directors' Deferral Plan demonstrates confidence in the company's future performance.

Future Outlook

The acquired shares will be settled in shares of common stock following Fyrwald's separation from service.

Industry Context

Director share acquisitions are common and can be seen as a positive sign, indicating confidence in the company's prospects. However, they are also scrutinized for potential insider trading issues.

Stakeholder Impact

• The acquisition could have a slightly positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates